1. Volume 72, Issue 4, Pages 557-564 (October 2017)
Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma 
Sumanta K. Pal, Guru Sonpavde, Neeraj Agarwal, Nicholas J. Vogelzang, Sandy Srinivas, Naomi B. Haas, Sabina Signoretti, Bradley A. McGregor, Jeremy Jones, Richard B. Lanman, Kimberly C. Banks, Toni K. Choueiri 
European Urology 
Volume 72, Issue 4, Pages (October 2017)
DOI: /j.eururo
Copyright © 2017 European Association of Urology Terms and Conditions

2. Fig. 1
(A) Characterization of first-line and postfirst-line therapy and (B) distribution of treatments amongst 99 patients with available treatment-related data. (Note: not all patients receiving first-line therapy receive subsequent postfirst-line therapy; please refer to Material and Methods).
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions

3. Fig. 2
Cumulative genomic alterations in circulating tumor DNA across (A) 220 patients with renal cell carcinoma (any histology) and (B) 89 patients with documented clear cell renal cell carcinoma.
VUS=variants of uncertain significance.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions

4. Fig. 3
Frequency of selected genomic alterations (GAs) according to histology.
ALL=acute lymphoblastic leukemia.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions

5. Fig. 4
Notable differences in genomic alteration (GA) frequency in patients documented as receiving first-line therapy versus postfirst-line therapy (p values were as follows: TP53: p=0.02; NF1: p=0.01; VHL: p=0.26; EGFR: p=0.6; PIK3CA: p=0.3).
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions